Table 5.

Diagnostic characteristics of urine NGAL for CI-AKI stage II, stratified by baseline and postoperative time in all patient (5A), CKD stage III and CKD stage IV (5B)

5A
All patients (N = 130)
	ROC (95% CI)	Cut point (ng/ml)	Sensitivity (%)	Specificity (%)
uNGAL
baseline	0.76 (0.65 to 0.88)	82	100	70
3 h	0.86 (0.76 to 0.97)	135	100	77
6 h	0.9 (0.84 to 0.97)	264	100	87
12 h	0.85 (0.74 to 0.96)	204	100	79
18 h	0.8 (0.72 to 0.88)	186	100	76
24 h	0.78 (0.7 to 0.86)	175	100	74
Delta of uNGAL
0-3 h	0.87 (0.77 to 0.97)	53	100	81
0-6 h	0.93 (0.86 to 0.99)	121	100	87
0-12 h	0.82 (0.67 to 0.98)	65	100	71
0-18 h	0.77 (0.63 to 0.91)	83	100	67
0-24 h	0.76 (0.64 to 0.88)	61	100	68
5B
	CKD stage III (N = 100)				CKD stage IV (N = 30)
	ROC (95% CI)	Cut point (ng/ml)	Sensitivity (%)	Specificity (%)	ROC (95% CI)	Cut point (ng/ml)	Sensitivity (%)	Specificity (%)
uNGAL
baseline	0.88 (0.0 to 1.0)	143	100	88	0.60 (0.42 to 0.79)	82	100	59
3 h	0.92 (0.0 to 1.0)	220	100	92	0.74 (0.48 to 1.0)	135	100	63
6 h	0.93 (0.0 to 1.0)	264	100	93	0.80 (0.56 to 1.0)	281	100	71
12 h	0.83 (0.0 to 1.0)	208	100	83	0.77 (0.51 to 1.0)	204	100	65
18 h	0.83 (0.0 to 1.0)	226	100	83	0.67 (0.48 to 0.85)	186	100	63
24 h	0.81 (0.0 to 1.0)	204	100	81	0.70 (0.52 to 0.87)	175	100	68
Delta of uNGAL
0-3 h	0.84 (0.0 to 1.0)	77	100	84	0.88 (0.72 to 1.0)	53	100	82
0-6 h	0.90 (0.0 to 1.0)	121	100	90	0.91 (0.77 to 1.0)	197	100	86
0-12 h	0.72 (0.0 to 1.0)	65	100	72	0.88 (0.68 to 1.0)	120	100	78
0-18 h	0.69 (0.0 to 1.0)	83	100	69	0.78 (0.61 to 0.95)	102	100	71
0-24 h	0.70 (0.0 to 1.0)	61	100	70	0.79 (0.60 to 0.98)	91	100	71